Experts Warn GLP-1 Drugs Alone Won't Solve Obesity Crisis
Public health experts argue that focusing solely on GLP-1 medications for obesity overlooks the systemic drivers of the epidemic, primarily the food
GLP-1 receptor agonists like Ozempic are powerful tools for treating obesity, but relying on them alone risks ignoring the root causes of the epidemic. This warning comes from Laura Schmidt, PhD, of the University of California San Francisco, in a new perspective published in Science with co-author Luc Hagenaars, PhD, of Amsterdam University Medical Center.
Schmidt argues the current "Ozempic era" must be paired with strong public health policies targeting the food environment. She says viewing these drugs as a magic bullet for a systemic problem is a mistake with historical precedent.
Medicalizing Obesity Misses the Point
Defining obesity purely as a medical condition needing pharmaceutical treatment takes focus away from the food environment as the primary driver. Schmidt warns this approach sets up a scenario where medications reach high-income countries first, potentially exacerbating global health disparities. She cites pressure from pharmaceutical companies on bodies like the World Health Organization (WHO) as a historical pattern that could repeat.
A prior systems analysis conducted by Schmidt and Hagenaars found the biggest barrier to solving obesity is the widespread belief that it is an individual's responsibility. Schmidt points to clinical trial evidence showing ultra-processed foods cause overeating and weight gain. Medicalizing the problem, she contends, moves efforts in the wrong direction when the driver is clear.
Treatment and Prevention Must Coexist
Schmidt believes treatment and prevention strategies can and must work together. She notes the WHO is advocating for both equitable distribution of GLP-1 medications and food environment reforms. "We can have GLP-1s for people who already have cardiometabolic disease and they seem very effective," Schmidt said. "So we can have that for the people who are already suffering and then we can be preventing at the same time the emergence of more obesity, especially in kids."
The challenge lies in a commercial landscape where many industries are seeking profit. Food, pharmaceutical, and supplement companies are all jumping on the bandwagon, potentially driving access primarily toward wealthier populations.
Calling for Tobacco-Style Regulations
The experts argue for implementing proven public health measures modeled on tobacco control. Schmidt states that WHO has a challenging job ahead in leading this regulatory charge. Effective strategies include taxation, warning labels, school-based interventions, and curbs on commercial marketing, especially ads targeting children.
"It should come as no surprise to anyone that tobacco-style regulations -- warning labels, taxation, curbs on marketing -- work really well for ultraprocessed foods," Schmidt explained. She notes the industries use similar product development approaches, making similar regulatory responses logical. The goal is to create guardrails for the GLP-1 era that address the epidemic's systemic causes while ensuring equitable access to effective treatments.
